We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-12.45%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$201M
AUM Growth
-$88.3M
Cap. Flow
-$46.1M
Cap. Flow %
-22.95%
Top 10 Hldgs %
75.88%
Holding
39
New
2
Increased
12
Reduced
2
Closed
9

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$12.7M
2
ARVN icon
Arvinas
ARVN
+$2.29M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$2.25M
4
ASND icon
Ascendis Pharma A/S
ASND
+$2.25M
5
FOLD
Amicus Therapeutics
FOLD
+$2.11M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$22M
2
SAGE
Sage Therapeutics
SAGE
+$16.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.4M
4
CLVT icon
Clarivate
CLVT
+$11.9M
5
BHC icon
Bausch Health
BHC
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVCPW
26
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$34.6K 0.02%
490,000
– –
LSBPW
27
DELISTED
LakeShore Biopharma Warrants
LSBPW
$17.1K 0.01%
489,999
– –
GATEW
28
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$13.5K 0.01%
735,000
– –
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
– –
-241,690
Closed -$22M
BHC icon
30
Bausch Health
BHC
$1.8B
– –
-1,165,000
Closed -$9.32M
CLVT icon
31
Clarivate
CLVT
$1.53B
– –
-1,247,406
Closed -$11.9M
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-797,527
Closed -$14.4M
SAGE
33
DELISTED
Sage Therapeutics
SAGE
– –
-357,765
Closed -$16.8M
HPLTW
34
DELISTED
Home Plate Acquisition Corporation Warrant
HPLTW
$0 ﹤0.01%
690,000
– –
CCV.WS
35
DELISTED
Churchill Capital Corp V Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
CCV.WS
$0 ﹤0.01%
612,000
– –
AFTR.WS
36
DELISTED
AfterNext HealthTech Acquisition Corp Warrants
AFTR.WS
– –
-366,666
Closed -$31.8K
CPAAW
37
DELISTED
Conyers Park III Acquisition Corp. Warrants
CPAAW
– –
-571,666
Closed -$28.6K
TWCBW
38
DELISTED
Bilander Acquisition Corp. Warrant
TWCBW
– –
-183,749
Closed -$9.33K
CORS.WS
39
DELISTED
Corsair Partnering Corporation Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CORS.WS
– –
-334,666
Closed –
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Finepoint Capital held 39 positions worth $201M, down 31% from $289M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Finepoint Capital withdrew a net $46.1M in Q3 2023, closing 9 positions and reducing 2 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Technology.

Against the trend, Finepoint Capital opened a new position in Revolution Medicines worth $11.8M.

  • Finepoint Capital's largest Q3 2023 buy was Revolution Medicines: 427,000 shares worth $11.8M.
  • Finepoint Capital added most to Arvinas in Q3 2023, an estimated $2.29M increase.
  • Finepoint Capital's biggest Q3 2023 reduction was Acadia Pharmaceuticals, cutting an estimated $7.89M.
  • Finepoint Capital fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $22M.
  • Finepoint Capital's ten largest holdings make up 76% of its $201M portfolio in Q3 2023.
  • Finepoint Capital opened 2 new positions and closed 9 in Q3 2023.
  • Finepoint Capital's portfolio value fell 31% quarter-over-quarter to $201M.

Based on Finepoint Capital's 13F filing for Q3 2023, filed 13 Nov 2023.